相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen
Qingyu Xu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis
Matheus F. Bezerra et al.
BLOOD (2020)
Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia
Yusuke Fujiwara et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2019)
Acute Myeloid Leukemia, Version 3.2019
Martin S. Tallman et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Nicholas J. Short et al.
LANCET HAEMATOLOGY (2019)
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia
S. Wang et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2018)
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
Ann-Kathrin Eisfeld et al.
LEUKEMIA (2018)
Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia
Jiayu Huang et al.
LEUKEMIA & LYMPHOMA (2018)
Next-generation sequencing-based genetic landscape and its clinical implications for Chinese acute myeloid leukemia patients
Xin-xin Cao et al.
CANCER CELL INTERNATIONAL (2018)
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Hartmut Doehner et al.
LEUKEMIA (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Lars Bullinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Emerging therapies for acute myeloid leukemia
Caner Saygin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Acute myeloid leukaemia genomics
Michael Medinger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
David Grimwade et al.
BLOOD (2016)
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2016)
Genetic alterations and their clinical implications in older patients with acute myeloid leukemia
C-H Tsai et al.
LEUKEMIA (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia
Jianyong Li et al.
ONCOTARGET (2015)
Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations
Robert S. Ohgami et al.
MODERN PATHOLOGY (2015)
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients
R. Kihara et al.
LEUKEMIA (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
S. Schnittger et al.
LEUKEMIA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value
Marta Pratcorona et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations
Wen-Chien Chou et al.
BLOOD (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
U Creutzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The difficult problem of acute myeloid leukemia in the older adult
RM Stone
CA-A CANCER JOURNAL FOR CLINICIANS (2002)
分享论文
